Fluent Financial LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,407 shares of the company’s stock after purchasing an additional 1,461 shares during the quarter. Johnson & Johnson makes up approximately 3.6% of Fluent Financial LLC’s holdings, making the stock its 4th biggest position. Fluent Financial LLC’s holdings in Johnson & Johnson were worth $6,601,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Morton Brown Family Wealth LLC increased its stake in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares during the period. Goodman Advisory Group LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at $39,000. Cardinal Capital Management Inc. increased its stake in shares of Johnson & Johnson by 333.3% during the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after buying an additional 200 shares during the period. First Bank & Trust grew its stake in Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after purchasing an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $84,000. 67.94% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on JNJ. StockNews.com initiated coverage on Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Citigroup boosted their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. SVB Leerink decreased their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday. Atlantic Securities cut their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Finally, Morgan Stanley dropped their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $181.75.
Johnson & Johnson Price Performance
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.
Insider Activity at Johnson & Johnson
In other news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Robert J. Decker sold 16,928 shares of the stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,707,775. The disclosure for this sale can be found here. Insiders sold a total of 277,886 shares of company stock valued at $48,550,549 over the last three months. 0.35% of the stock is owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.